A Real World Study of Apatinib in Treatment of Patients With Gastric Carcinoma
A Real World Study of Apatinib in Treatment of Patients With Gastric Carcinoma
The study was designed to evaluate the efficacy and safety of apatinib in the treatment of
 patients with gastric carcinoma.
The study is a real-world non-interventional retrospective study and will collect the
 original medical records of patients with gastric carcinoma treated with apatinib from 2015
 to 2018 in Henan Cancer Hospital. Clinical data such as patient demographic, history of
 treatments, tumor biological characteristics and adverse events will be analyzed to evaluate
 the efficacy and safety of apatinib and explore the risk factors of prognosis in patients
 with gastric carcinoma.
Inclusion Criteria:

 1. Pathologically or cytologically confirmed gastric or residual gastric or
 gastroesophageal junction carcinoma;

 2. Patients received apatinib treatment at least once.

 Exclusion Criteria:

 1. No specific exclusion criteria in this real world study.